{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:46:34Z","timestamp":1757454394002,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet therapy (DAPT) for 12 months. Since bleeding is the main Achilles' heel of DAPT, in recent years several randomized controlled trials have evaluated the safety and efficacy of de-escalation of DAPT with respect to ischaemic and bleeding endpoints. These trials can be broadly divided into studies evaluating a shorter duration of DAPT, and those studies in which DAPT that includes a potent P2Y<jats:sub>12<\/jats:sub> inhibitor, such as prasugrel or ticagrelor, is compared to less intense DAPT, mainly clopidogrel or reduced-dose prasugrel. We sought to evaluate the studies assessing de-escalation of DAPT in patients with ACS undergoing PCI. We review the studies evaluating the strategies of de-escalation of DAPT intensity and those evaluating a strategy of de-escalation of DAPT duration in ACS patients undergoing PCI. We summarize the limitations of studies to date, gaps in evidence and make recommendations for future studies.<\/jats:p>","DOI":"10.3389\/fcvm.2022.1018649","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:26:48Z","timestamp":1666247208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review"],"prefix":"10.3389","volume":"9","author":[{"given":"Mohamed","family":"Farag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visvesh","family":"Jeyalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.111.060871","article-title":"Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"125","author":"Ndrepepa","year":"2012","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jacc.2015.05.053","article-title":"Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence","volume":"66","author":"Montalescot","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","article-title":"Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2013 randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"68","author":"Tang","year":"2016","journal-title":"J Cardiovasc Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/TCRM.S108965","article-title":"Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome","volume":"12","author":"Wang","year":"2016","journal-title":"Ther Clin Risk Manag."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2017.11.008","article-title":"1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor","volume":"71","author":"Motovska","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the global leaders trial","volume":"10","author":"Vranckx","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the smart-choice randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA."},{"key":"B33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the tico randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"33054","DOI":"10.1038\/srep33054","article-title":"Six versus twelve months clopidogrel therapy after drug-eluting stenting in patients with acute coronary syndrome: an ISAR-SAFE study subgroup analysis","volume":"6","author":"Lohaus","year":"2016","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2013.282183","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in east asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost."},{"key":"B41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4070\/kcj.2021.0293","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with STEMI","volume":"52","author":"Ki","year":"2022","journal-title":"Korean Circ J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s11239-020-02240-2","article-title":"Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis","volume":"51","author":"Jeong","year":"2021","journal-title":"J Thromb Thrombolysis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e011990","DOI":"10.1161\/CIRCINTERVENTIONS.122.011990","article-title":"Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis","volume":"15","author":"Kuno","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e003577","DOI":"10.1161\/CIRCINTERVENTIONS.116.003577","article-title":"Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES study (assessment of dual antiplatelet therapy with drug-eluting stents)","volume":"10","author":"Yu","year":"2017","journal-title":"Circ Cardiovasc Interv."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1018649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:26:49Z","timestamp":1666247209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1018649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2022.1018649"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1018649","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1018649"}}